SCHEDULE: FMR LLC Lowers Seres Therapeutics Stake to 3.1%
Beneficial Ownership Report (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have filed an Amendment No. 14 to Schedule 13G, reporting a beneficial ownership of 3.1% in Seres Therapeutics Inc. common stock as of June 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson filed an Amendment No. 14 to Schedule 13G regarding their beneficial ownership of Seres Therapeutics Inc. common stock.
- As of June 30, 2025, FMR LLC and Abigail P. Johnson collectively beneficially own 268,704 shares of Seres Therapeutics Inc. common stock.
- This aggregate amount represents 3.1% of the class of common stock outstanding.
- FMR LLC holds sole voting power over 268,568 shares and sole dispositive power over 268,704 shares.
- Abigail P. Johnson holds sole dispositive power over 268,704 shares, with no sole or shared voting power.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a reduction in stake below the 5% threshold. This is generally neutral in sentiment, as it does not provide operational or financial performance data, though a decrease in institutional ownership could be viewed with slight caution by some investors.
Positives
- NA
Negatives
- The beneficial ownership stake of FMR LLC and Abigail P. Johnson has decreased to 3.1%, falling below the 5% threshold that typically triggers initial Schedule 13G filings, which may indicate a reduced conviction or portfolio rebalancing by the institutional investor.
Risks
- This filing is a disclosure of beneficial ownership and does not detail specific risks related to Seres Therapeutics Inc.'s operations or financial performance. However, a reduction in a significant institutional stake could be interpreted by some investors as a minor signal of reduced confidence, which might indirectly affect investor sentiment.
Future Outlook
This Schedule 13G filing is a report on beneficial ownership and does not contain any forward-looking statements or guidance regarding Seres Therapeutics Inc.'s future performance or strategic outlook.
Industry Context
This filing is a routine disclosure of an institutional investor's stake in a publicly traded company. It does not provide insights into broader industry trends or competitive dynamics within the biotechnology sector, but rather reflects a specific investment decision by FMR LLC regarding Seres Therapeutics Inc.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Structure (FMR LLC) | Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares of FMR LLC (49% voting power). They have a shareholders' voting agreement to vote Series B shares in accordance with the majority vote, potentially forming a controlling group with respect to FMR LLC under the Investment Company Act of 1940. This relates to the internal governance of the reporting entity (FMR LLC), not Seres Therapeutics Inc. | NA | This detail clarifies the control structure of FMR LLC, the reporting entity, and its affiliates (FMR Reporters) in relation to their beneficial ownership reporting. It does not indicate changes in the corporate governance of Seres Therapeutics Inc. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's reduced stake in the company, which may influence investor sentiment or perceptions of institutional confidence.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 08/05/2025 | Date the Schedule 13G Amendment No. 14 was signed and filed. |
Keywords
Seres Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investor, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.